MARK G FOLETTA
CIK 1236389 · EVP & Chief Financial Officer · last filed 2026-06-01
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$5.43M
Companies
10
Total Filings
117
Lifetime Open-Market Net
-$7.75M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DXCM | Director | 63,183 | $75.37 | $4.76M | -$5.33M | 37 | 2026-06-01 |
| AMN | Director | 21,598 | $30.80 | $665.2K | -$1.09M | 20 | 2026-05-04 |
| ENTA | Director | — | $11.90 | — | $0 | 7 | 2026-03-13 |
| Forte Biosciences, Inc. (TOCA) Delisted | EVP & Chief Financial Officer | 15,042 | — | — | $71.5K | 7 | 2019-10-04 |
| Regulus Therapeutics Inc. (RGLS) Delisted | Director | 81,910 | $8.16 | $668.4K | $76.4K | 7 | 2017-12-06 |
| AMN HEALTHCARE SERVICES INC (AHS) Delisted | Director | 5,532 | — | — | $0 | 4 | 2016-04-22 |
| BIOCEPT INC (BIOC) Delisted | Interim CFO | — | $0.43 | — | $0 | 1 | 2015-09-02 |
| AMBIT BIOSCIENCES CORP (AMBI) Delisted | Director | — | $0.54 | — | $0 | 2 | 2014-11-12 |
| AMYLIN PHARMACEUTICALS INC (AMLN) Delisted | SVP, Chief Financial Officer | 81,344 | — | — | -$1.48M | 25 | 2012-07-26 |
| ANADYS PHARMACEUTICALS INC (ANDS) Delisted | Director | — | — | — | $0 | 6 | 2011-05-27 |
Recent Filings · Page 5 of 12
117 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-03-04 | DXCM | Sell (S) | −1,000 | -$277.1K | EDGAR |
| 2020-02-05 | DXCM | Sell (S) | −1,000 | -$237.8K | EDGAR |
| 2020-01-07 | DXCM | Sell (S) | −1,000 | -$218.1K | EDGAR |
| 2019-12-05 | DXCM | Sell (S) | −1,000 | -$227.6K | EDGAR |
| 2019-10-04 | Forte Biosciences, Inc. (TOCA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-04 | DXCM | Mixed | +3,055 | $3 | EDGAR |
| 2019-05-29 | Forte Biosciences, Inc. (TOCA) Delisted | Buy (P) | +5,000 | $21.5K | EDGAR |
| 2019-05-17 | DXCM | Sell (S) | −1,000 | -$121.9K | EDGAR |
| 2019-04-19 | AMN | Mixed | +2,153 | $0 | EDGAR |
| 2019-04-17 | DXCM | Sell (S) | −1,000 | -$119.0K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.